This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Results of changed treatment for retinoblastoma

Results of changed treatment for retinoblastoma
Reviewed by Fiona Rowe

1 February 2015 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus

Systemic chemotherapy was adopted in Kobe in 1996. In this study the authors analyse the clinical manifestations and results of treatment for patients with retinoblastoma since then. This review is of 43 eyes of 34 patients. Those with follow-up to a minimum of one year were included – 25 monocular and nine binocular cases with a median age at first examination of 13 months (22 days to six years and two months). Three patients had a family history of retinoblastoma. The youngest case was one of these three children. The mean observation period was 10.6. months ±53 (16-211). Clinical presentation at first examination included leukocoria (33) and exotropia (one). There was no correlation between age at first examination and classification stage of retinoblastoma. Nineteen eyes were in the initial enucleation group and 24 eyes in the initial preservation plan. Of the latter, 11 eyes continued preservation and 13 discontinued. Of the preservation cases, seven were enucleated because of poor tumour reduction, five showed tumour recurrence, one was enucleated due to secondary glaucoma, one developed secondary cataract and one patient had multi-organ metastases and died. Systemic chemotherapy with vincristine after 2000 had slightly better outcomes than that with ifosfamide before 1999. The study demonstrated that in cases that eventually need enucleation, chemotherapy can significantly delay this with the advantage that the orbit and eyelid can develop normally first and thus reduce the occurrence of facial defects caused by orbit and lid deformities following early enucleation. Eye preservation treatment was performed for a higher proportion of advanced cases among bilateral cases than monocular cases.

Clinical manifestations and treatment of retinoblastoma in Kobe Children’s Hospital for 16 years.
Okimoto S, Nomura K.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2014;51:222-9.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency